GlassScriptPhysician profile
Raymond J Matta
NPI 1235206665
$9,841.91
in general payments reported to CMS, 2019-2025
22 companies · $824 in 2025
The $824 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,388 · 2020: $759 · 2021: $1,627 · 2022: $1,106 · 2023: $988 · 2024: $1,151 · 2025: $824.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,962.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,962.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,694.05 | 2019-2025 | Biktarvy |
| Astrazeneca Pharmaceuticals LP | $1,576.60 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Janssen Products, LP | $1,134.99 | 2019-2022 | |
| Novo Nordisk INC | $786.40 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Esperion Therapeutics, INC. | $751.57 | 2020-2024 | Nexletol |
| Glaxosmithkline, LLC. | $581.18 | 2019-2023 | Arexvy, Trelegy Ellipta |
| Pfizer INC. | $529.34 | 2019-2025 | |
| Viiv Healthcare Company | $417.23 | 2019 | |
| Amarin Pharma, INC. | $415.77 | 2019 | |
| Janssen Pharmaceuticals, INC | $379.94 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $345.64 | 2022-2025 | Verquvo, Capvaxive, Gardasil 9 |
| Amgen INC. | $293.96 | 2019-2025 | Krystexxa |
| Novartis Pharmaceuticals Corporation | $241.80 | 2019-2024 | |
| Idorsia Pharmaceuticals US INC | $210.87 | 2022-2023 | Quviviq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $165.36 | 2023-2024 | Jardiance |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $108.02 | 2019-2025 | Camzyos |
| Abbvie INC. | $58.51 | 2025 | |
| Intercept Pharmaceuticals, INC. | $56.30 | 2022-2023 | Ocaliva |
| Nestle Healthcare Nutrition INC. | $50.10 | 2021-2022 | |
| Medtronic, INC. | $18.00 | 2022 | |
| Intra-Sana Laboratories | $13.49 | 2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Kowa Pharmaceuticals America, INC. | $12.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raymond Matta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.